Mitchell Jackson

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

Retrieved on: 
Friday, May 13, 2022

FARMINGTON HILLS, Mich., May 13, 2022 (GLOBE NEWSWIRE) --  Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • FARMINGTON HILLS, Mich., May 13, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • First Quarter Ended March 31, 2022 Financial Highlights
    As of March 31, 2022, Ocuphire had cash and cash equivalents of approximately $19.2 million.
  • The loss from operations for the quarter ended March 31, 2022 was $6.5 million, compared to $5.2 million for the quarter ended March 31, 2021.
  • Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day

Retrieved on: 
Monday, January 31, 2022

To access the R&D Day presentations live or for the recording, please click here .

Key Points: 
  • To access the R&D Day presentations live or for the recording, please click here .
  • Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia.
  • The company is currently enrolling subjects ina Phase 2b clinical trial of APX3330 to treat DR/DME (ZETA-1).
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January

Retrieved on: 
Wednesday, January 5, 2022

This update includes recent progress on Nyxol trials, the Companys cash position, and the announcement of an Investor R&D day in late January.

Key Points: 
  • This update includes recent progress on Nyxol trials, the Companys cash position, and the announcement of an Investor R&D day in late January.
  • A positive outcome in MIRA-3 will position us to submit an NDA for Nyxol for RM in late 2022.
  • We look forward to providing clinical updates on Nyxol in presbyopia and RM as well as APX3330 in diabetic retinopathy at our upcoming Virtual Investor R&D Day.
  • Completed Enrollment of LYNX-1 Study in Night Vision Disturbances: Enrollment has been completed in the LYNX-1 Phase 3 clinical trial investigating Nyxol for the treatment of NVD.